Drug and Therapeutics Bulletin 1998;36:86-88
Copyright © 1998 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Reboxetine - another new antidepressant

Relevant BNF section: 4.3.4

{blacktriangledown}Reboxetine (Edronax - Pharmacia & Upjohn) is a new antidepressant drug introduced last year for the acute treatment and, in patients who respond, the maintenance treatment of depression. It is marketed as a "new selective noradrenaline reuptake inhibitor" (or 'NARI'). The manufacturer claims that reboxetine "not only lifts depressed mood" but also "helps restore social interaction", with "significantly better outcome in terms of social functioning" than fluoxetine. We assess these claims and consider the place of reboxetine in therapy.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1998 BMJ Publishing Group Ltd.